| dc.contributor.author | Koech, DK | |
| dc.contributor.author | Obel, AO | |
| dc.contributor.author | Minowada, J | |
| dc.contributor.author | Hutchinson, VA | |
| dc.contributor.author | Cummins, JM | |
| dc.date.accessioned | 2013-06-21T09:32:17Z | |
| dc.date.available | 2013-06-21T09:32:17Z | |
| dc.date.issued | 1990-06 | |
| dc.identifier.citation | Mol Biother. 1990 Jun;2(2):91-5. | en |
| dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/1973045 | |
| dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/37345 | |
| dc.description.abstract | Thirty eight symptomatic and two asymptomatic patients seropositive for human immunodeficiency virus type-1 (HIV-1) were treated with a natural human interferon alpha (HuIFN alpha). Patients were given 2 IU/kg HuIFN alpha orally once daily in powdered maltose held in the mouth to promote mucosal absorption. This oral immunomodulating HuIFN alpha therapy resulted in an increase in CD4+ lymphocytes, an increase in weight, and a dramatic alleviation of clinical symptoms related to HIV-1 infection. | en |
| dc.language.iso | en | en |
| dc.publisher | University of Nairobi | en |
| dc.title | Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1). | en |
| dc.type | Article | en |
| local.publisher | College of Health Sciences,University of Nairobi | en |
